<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317743</url>
  </required_header>
  <id_info>
    <org_study_id>NOV140101-101/ID-VDP-101</org_study_id>
    <nct_id>NCT03317743</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety &amp; Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX-1197HCl) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National OncoVenture</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Idience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to&#xD;
      evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum&#xD;
      tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV140101 (IDX-1197).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1 dose escalation study of NOV140101 (IDX-1197) to evaluate the&#xD;
      safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of&#xD;
      IDX-1197 in patients with advanced solid tumors after failure of standard of care. DLTs will&#xD;
      be assessed as the primary endpoint in this trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">December 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>NOV140101 (IDX-1197)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOV140101 (IDX-1197)</intervention_name>
    <description>The dose levels will be escalated following a 3+3 dose escalation scheme.</description>
    <arm_group_label>NOV140101 (IDX-1197)</arm_group_label>
    <other_name>IDX-1197</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥19 year old patients with histologically or cytologically confirmed metastatic or&#xD;
             unresectable advanced solid tumors&#xD;
&#xD;
          -  Life expectancy ≥12 weeks&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test outcome&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Lesions measured by tumor markers or CT/MRI and evaluable according to RECIST v1.1&#xD;
&#xD;
          -  Patient must have adequate organ function as indicated by the following laboratory&#xD;
             values independent of transfusion within 2 weeks:&#xD;
&#xD;
               1. ANC ≥ 1,500/mm³&#xD;
&#xD;
               2. Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0g/dL&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5×ULN&#xD;
&#xD;
               5. Total bilirubin ≤ 1.5×ULN&#xD;
&#xD;
               6. AST, ALT ≤ 3×ULN (≤ 5×ULN for patients with liver metastasis or liver cell&#xD;
                  cancer)&#xD;
&#xD;
               7. PT and aPTT ≤ 1.5×ULN&#xD;
&#xD;
               8. UPC &lt; 1.0 g/g (one re-test is allowed if positive (≥ 1))&#xD;
&#xD;
          -  Patients must provide written informed consent to voluntary participation in this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity reactions to any of the components of the investigational&#xD;
             product or other drugs of the same class&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled&#xD;
             hypertension (systolic/diastolic blood pressure &gt;140/90mmHg), or other clinically&#xD;
             significant cardiovascular abnormalities in the opinion of the investigator&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  Acute coronary syndrome (unstable angina pectoris or myocardial infarction) within the&#xD;
             past 6 months&#xD;
&#xD;
          -  Major electrocardiogram (ECG) abnormalities in the opinion of the investigator&#xD;
&#xD;
          -  Severe infection or severe traumatism&#xD;
&#xD;
          -  Pneumonia or respiratory symptoms, such as dyspnea, cough, and fever, requiring&#xD;
             treatment and other conditions likely to be accompanied by hypoxemia&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past 3 months&#xD;
&#xD;
          -  Symptomatic or uncontrolled central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a&#xD;
             minor surgery&#xD;
&#xD;
          -  Radiotherapy, hormone therapy, or chemotherapy within 2 weeks prior to baseline from&#xD;
             which toxicities not recovered to ≤grade 1&#xD;
&#xD;
          -  &gt;4 weeks of persistent Grade 3 (NCI-CTCAE v4.03) hematologic toxicities from prior&#xD;
             anticancer treatment&#xD;
&#xD;
          -  History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test results&#xD;
             indicative of the risk of MDS or acute myelocytic leukemia&#xD;
&#xD;
          -  Ongoing or anticipated treatment with antiplatelet drugs (aspirin, clopidogrel, etc.)&#xD;
             or anticoagulant drugs (warfarin, heparin, etc.) during the study&#xD;
&#xD;
          -  Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids&#xD;
&#xD;
          -  Ongoing or past treatment with immunosuppressants within 14 days prior to the first&#xD;
             dose of study treatment, except for intranasal, inhaled, topical, or locally injected&#xD;
             (e.g., intraarticular injection) steroids&#xD;
&#xD;
          -  History of serious gastrointestinal bleedings within 12 weeks prior to screening or&#xD;
             presence of diseases that may affect oral drug absorption (e.g., malabsorption&#xD;
             syndrome, active peptic ulcer)&#xD;
&#xD;
          -  History of human immunodeficiency virus infection or active hepatitis B or C infection&#xD;
             or ongoing uncontrolled chronic infectious disease&#xD;
&#xD;
          -  Pregnant or lactating women or patients planning to become pregnant during the study&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to screening&#xD;
&#xD;
          -  Individual considered ineligible for this study for other reasons, in the opinion of&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

